Determination of plasma fibronectin and serum C-reactive protein in patients with cerebrovascular events

International Journal of Clinical Practice

Volumn 57, Issue 2, 2003, Pages 91-95

  Pençe, Sadrettin ^a   Yilmaz, G ^b   Yilmaz, N ^a   Kocoglu, H ^a   Namiduru, E ^a   Yuncu M ^a   Gokalp N ^c  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Gaziantep State Hospital   (Turkey)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; FIBRONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CEREBROVASCULAR DISORDERS; FEMALE; FIBRONECTINS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 0037347858     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Avo Esch T, Stefano GB. Proinflammation: a common denominator or initiator of different pathophysiological disease proceses. Med Sci Monit 2002; 8(5): 1-9.
2. Bova IY, Bornstein NM, Korcezyn AD. Acute infection as a risk factor for ischemic stroke. Stroke 1996; 27: 2204-2206.
3. Grav AJ. Infection, inflammation and cerebrovasculer ischemia. Neurology 1997; 49(supp 14): 547-551.
4. Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137: 69-78.
5. Arvin B, Neville LF, Barone FC, Feverstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996; 20: 445-452.
6. Mahrschladt MF, Maat MPM, Westendorp RGJ, Smelt AHM. C-reactive protein in patients with familial hypercholesterolemia. Atherosclerosis 2001; 157: 491-494.
7. Hashimoto H, Kitawaga K, Hovgako H et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104: 63-67.
8. Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein in and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-2579.
9. Song Sk, Kim HK, Shim N, Jee SH. Plasma fibronectin levels in ischemic heart disease. Atherosclerosis 2001; 154: 449-453.
10. Bizbiz L, Labart-Robert J, Aperavitch A, Robert L, and the EVA group. Cardiovascular determinants of plasma fibronectin in an elderly population. Arch Gerontol-Geriatr 1997; 25: 201-209.
11. Robert LJ, Marques MA, Naoye S et al. Plasma fibronectin in French centenarians. Arch Gerontol Geriatr 2000; 31: 95-105.
12. Wong VY, Laping NJ, Nelson AH et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol 2001; 134(5): 977-984.
13. Grimm D, Huber M, Jabusch HC et al. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor. J Mol Cell Cardiol 2001; 33(3): 487-501.
14. Takasahi I, Chobanian AV, Sarzani K, Brecher P. Effect of hypertension on fibronectin expression on the rat aorta. J Biol Chem 1990; 265: 21935-21939.
15. Friedewald WT, Levy RI, Fredricson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke; an independent prognostic factor. Stroke 2001; 32: 917-924.
17. Kanters SD, Banga JD, Algra A et al. Plasma levels of cellular fibronectin in diabetes. Diabetes Care 2001; 24: 323-328.
18. Canova CR, Courtin C, Reinhart WH. C-reactive protein (CRP) in cerebro-vascular events. Atherosclerosis 1999; 47(1): 49-53.
19. Di Napoli M. C-reactive protein and acute phase of ischaemic stroke. BMJ 2001; 322: 1605.
20. Arand M, Melzner H, Kinzl L et al. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbeks Arch Surg 2001; 386: 241-248.
21. Di Napoli M, Di Gianfilippo G, Sollectio A, Bocola V. C-reactive protein and outcome after first ever ischemic stroke. Stroke 2000; 31: 238-239.
22. Weiss CR, Arai AE, Bui M et al. Arterial wall MRI chaacteristics are associated with elevated serum markers of inflammation in humans. J Magn Res Imaging 2001; 14: 698-704.
23. Hertel M, Tretter Y, Alzheimer C, Werne S. Connective tissue growth factor: a novel player in tissue reorganisation after brain injury? Eur J Neurosci 2000; 12: 376-380.
24. Nishizawa Y, Fukai Y, Natori R et al. Mesangial cell apoptosis induced by a fibrinogen fragment. Apoptosis 1998; 3: 407-412.
25. Dirnag U, Iadecola C, Moskowitz MA. Pathobiology of ishaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-397.
26. Stubbs TM, Hazarchick J, Horger EO. Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. Am J Obstet Gynecol 1984; 150: 885-887.
27. Gobel U, Theilen H, Kuschinsky W. Congruence of total and perfused capillary network in rat brains. Circ Res 1990; 66(2): 271-281.
28. Kwakkel G, Wagennar RC, Kollen BJ, Lankhorst GJ. Predicting diability in stroke: a critical review of the literature. Age Ageing 1996; 25: 479-489,
29. Sönmez H, Suer S, Kokoglu E et al. The importance of Lp(a)-fibronectin interaction in atherogenesis. Haematologia 1997; 28: 149-153.
30. Contard F, Sabri A, Glukhova M et al. Arterial smooth muscle cell phenotype in stroke-prone spontaneously hypertensive rats. Hypertension 1993; 22(5): 665-676.
31. McGeer PL, Zhu SG, Dedhar S. Immunostaining of human brain capillaries by antibodies to very late antigens. J Neuroimmunol 1990; 26(3): 213-218.
32. Bakunts GO, Kulberg A, Oganian RR et al. Fibronectin levels in the blood and cerebrospinal fluid in cerebrovascular disease. Zh Nevropatol Psikhiatr 1989; 89(9): 35-38.
33. Franzini C. Need for correct estimates of biological variation. Clin Chem Lab Med 1998; 36: 131-132.
34. Chen HC, Guh JY, Shin SJ, Lai YH. Pravastatin superoxide and fibronectin production of glomerular mesangial cells induced by oxidized LDL and high glucose. Atherosclerosis 2002; 160: 141-146.
35. Sato T, Roy S. Effect of high glucose on fibronectin expression and cell proliferaation in trabecular meshwork cells. Invest Ophthalmol Vis Sci 2002; 43(1): 170-175.
36. Righetti AE, Boer-Lima PA, Lopes de Faria JB. The presence of genetic hypertension stimulates early renal acumulation of fibronectin in experimental diabetes mellitus. Diabetologia 2001; 44: 2088-2091.
37. Miyazaki M, Takemura N, Watanabe S et al. Dietary docohexaenoic acid ameliorates, but rapeseed oil and safflower oil accelerate renal injury in stroke-prone spontaneously hypertensive rats as compared with soybean oil, which is associated with expression for renal transforming growth factor-β, fibronectin and renin. Biochim Biophys Acta 2000; 1483: 101-110.